Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KJ-103 phase I/IIa trial in TROP2-positive advanced solid cancers
ISRCTN15819396Phase 2Recruiting
- Sponsor
- Cancer Research UK
- Start
- Jun 2026
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of KJ-103 in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC), transitional cell carcinoma (TCC) and 2 more (5 arms), sponsored by Cancer Research UK. Primary endpoints: Dose for expansion, Dose-limiting toxicities in Module A and 3 more. Started Jun 2026; status: recruiting.
02
Drugs
KJ-103
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)transitional cell carcinoma (TCC)breast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN15819396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15819396.